According to a report by Bloomberg, CME Group Inc. (NASDAQ:CME) has received an average recommendation of “Moderate Buy” from ten analysts who have been covering the company. Out of these analysts, one has given the stock a sell rating, three have issued a hold rating, and six have rated it as a buy.
In further news, Director Daniel R. Glickman recently sold 750 shares of the company’s stock on August 9th at an average price of $206.09 per share, resulting in a total transaction value of $154,567.50. Following this sale, Glickman now holds 14,658 shares directly in the company, which are valued at approximately $3,020,867.22. This transaction was disclosed through a legal filing with the SEC and can be found through the provided hyperlink.
Additionally, CEO Terrence A. Duffy sold 30,000 shares of CME Group’s stock on August 18th at an average price of $203.95 per share, amounting to a total value of $6,118,500. After this sale, Duffy now holds 65,545 shares directly in the company with an estimated value of $13,367902.75.
It is important to note that in the last three months alone insiders have sold a total of 58,391 shares of CME Group’s stock worth approximately $11.905 million. As per current records available with the SEC filings on insider transactions reveal that corporate insiders currently own around 0.30% stake in the company.
CME Group last released its quarterly earnings data on July 26th where they reported earnings per share (EPS) of $2.30 for the quarter which beat analysts’ consensus estimates by $0.10 EPS However; during this period financial services provider also had revenue totaling about $$1.36 billion which surpassed analyst expectations set at $1.34 billion.
For the same quarter, CME Group had a return on equity (ROE) of 11.30% along with an impressive net margin of 56.88%. This quarterly revenue reflects an increased growth rate of 9.9% compared to the previous year’s figures. In the equivalent period last year, CME Group posted earnings per share (EPS) amounting to $1.97.
Analysts are predicting that CME Group will post earnings per share (EPS) of approximately $9.06 for the current fiscal year.
In conclusion, CME Group has received positive recommendations from analysts and continues to perform well in terms of its financial results. With recent insider selling by company executives, investors may wish to carefully monitor these developments as they make investment decisions related to the stock.
[bs_slider_forecast ticker=”CME”]
Analysis of CME Group: Multiple Analyst Perspectives, Institutional Interest, and Stock Performance
CME Group, a leading financial market company, has been recently analyzed by various analysts, each giving their own perspective on the stock and price targets. In a research report released on Thursday, July 27th, Citigroup raised their price objective on CME Group from $210.00 to $215.00 and also provided the stock with a “buy” rating.
Meanwhile, StockNews.com started coverage of CME Group in a research report on Thursday, August 17th. They have set a “hold” rating for the company but did not provide any specific price targets.
Rosenblatt Securities had a different view, increasing their price target for CME Group from $169.00 to $173.00 and giving the stock a “sell” rating in their research note provided on July 27th.
Barclays also released a research note on July 27th where they raised the price objective on CME Group from $215.00 to $230.00 and gave the company an “overweight” rating.
Finally, Bank of America altered their rating for CME Group from “underperform” to “neutral”, along with raising their target price for the stock from $167.00 to $204.00 in their research note dated September 6th.
It is noteworthy that institutional investors and hedge funds have shown significant interest in buying and selling shares of CME Group recently. Several investment firms have made new acquisitions of CME Group shares during different quarters this year. MayTech Global Investments LLC purchased a new stake in shares of CME Group during the fourth quarter valued at approximately $25,000 whereas CoreCap Advisors LLC acquired shares during the same period worth around $26,000.
Power Corp of Canada also entered the scene by acquiring shares worth approximately $26,000 in the first quarter while Silicon Valley Capital Partners made a similar purchase worth around $27,000 during that time frame. Cascade Investment Advisors Inc. joined the list of buyers by acquiring shares worth $27,000 during the first quarter.
These institutional investors and hedge funds currently hold a whopping 85.69% of the company’s stock, reflecting their confidence in CME Group’s potential.
Moving on to the stock performance, on Wednesday, shares of CME Group opened at $199.83. The company has been showing stability in its 50-day moving average, which stands at $202.03 and its two-hundred day moving average at $190.81. Over the past year, CME Group’s share price has ranged from a low of $166.54 to a high of $209.31.
Analyzing some financial metrics, CME Group boasts a favorable balance sheet with a debt-to-equity ratio of only 0.12, indicating strong financial health. Furthermore, the company maintains a solid current ratio and quick ratio of 1.02 each.
With a market capitalization estimated at $71.89 billion and a PE ratio of approximately 24.40, CME Group has secured its position as one of the industry’s key players.
Additionally, the stock carries a price-to-earnings-growth ratio (PEG) of 2.62 and holds a beta value of 0.41.
As investors continue to grapple with various analyst reports and evaluate recent trends in institutional investments, it remains to be seen how these factors will influence the future performance and direction of CME Group in the ever-evolving financial market landscape.
